by Lupus Foundation, Ohio | Oct 27, 2026 | Lupus Foundation of America, News & Events
Fate Therapeutics announced promising preliminary clinical trial results for FT819, an investigational CAR T-cell therapy for people living with systemic lupus erythematosus (SLE) with lupus nephritis (LN), a serious complication of lupus that affects the kidneys....
by Lupus Foundation, Ohio | Oct 23, 2026 | Lupus Foundation of America, News & Events
A new study of adults with systemic lupus erythematosus (SLE) found those with mental health diagnoses (depression, anxiety, and posttraumatic stress disorder (PTSD)) have much higher repeat emergency and hospital care use. This post was originally published on this...
by Lupus Foundation, Ohio | Oct 21, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EG-501 from Evergreen Therapeutics, an investigational oral treatment for adults with cognitive impairment associated with neuropsychiatric systemic lupus erythematosus (NPSLE),...
by Lupus Foundation, Ohio | Oct 21, 2026 | Lupus Foundation of America, News & Events
A new pooled analysis of adults with systemic lupus erythematosus (SLE) found commonly used patient-reported measures varied meaningfully in sensitivity to clinical changes in SLE, disease course and follow-up timing. This post was originally published on this...
by Lupus Foundation, Ohio | Oct 2, 2026 | Lupus Foundation of America, News & Events
A Phase I study of the investigational CAR-T cell therapy prulacabtagene leucel (prula-cel) found that some people with SLE, including those with lupus nephritis (LN), achieved remission and kidney-related responses after a single treatment. This post was originally...
by Lupus Foundation, Ohio | Sep 30, 2026 | Lupus Foundation of America, News & Events
A new study found that dietary supplement use is widespread among adults living with systemic lupus erythematosus (SLE), with more than 80% of participants reporting use of at least one supplement and more than half using two or more. This post was originally...
